Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.

Key facts

Study ID

NCT01188863

Run by

Lexicon Pharmaceuticals

People needed

15

Starts

2010-09-01

Last updated by the study team

2011-03-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 to 65 years of age
• Males and females of non-childbearing potential
• Diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening
• Fasting plasma glucose ≤240 mg/dL
• Body mass index <42 kg/sq m
• HbA1c of 7-11%
• C-peptide of ≥1.0 ng/mL
• Ability to provide written informed consent

You may not qualify if…

• History of type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketonic syndrome, incontinence, or nocturia
• Current use of any blood glucose-lowering agent other than metformin
• Exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening
• History of HIV, Hepatitis B, or Hepatitis C
• Surgery within 6 months of screening
• Donation or loss of >400 mL of blood or blood product within 8 weeks prior to start of study
• Use of proteins or antibodies within 12 weeks prior to screening. (Flu shots are allowed.)
• Exposure to any investigational agent or participation in an investigational trial within 30 days of the start of the study
• History of drug or alcohol abuse within 12 months prior to screening.

Where it is running

• Lexicon Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.